safey findings of emerald-1: durvalumab, bevacizumab and tace in hcc
Published 3 weeks ago • 50 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc
-
1:03
phase iii emerald-1: bevacizumab and durvalumab with tace improves pfs in unresectable hcc
-
0:55
exploring durvalumab bevacizumab tace in hepatocellular carcinoma: emerald-1 insights
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
12:05
biosafety levels 1 2 3 4 | laboratory safety levels.
-
9:57
how to tell the difference between untreated yellow sapphire vs beryllium treated yellow sapphire?
-
1:57
high-powered microscopes capture cancer cells in action
-
5:50
a phase ib single-arm study of bintrafusp alfa
-
1:22
first-in-human trial for tebentafusp in advanced melanoma shows promising safety profile
-
0:58
#myfaveelement: ge
-
2:52
safety in the lab 101
-
1:03
1 introduction
-
1:54
1 intro
-
9:46
tobias broger (find) and jack regnart (blue frontier) on bm2dx
-
7:20
tell me when it's safe (to open my eyes)
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer
-
2:46
unlocking the trove of fda clinical trials data